Back to Directory
Relamorelin
Performance & EnduranceGhrelin receptor agonist for diabetic gastroparesis and chronic nausea.
Key Benefits
- ✓Accelerates gastric emptying
- ✓Treats gastroparesis
- ✓Reduces chronic nausea
- ✓Improves GI symptoms
- ✓For diabetic gastroparesis
Dosing Information
Dosage Range
Under investigation
Frequency
Under investigation
Typical Duration
Clinical trials ongoing
Detailed Protocol
Under clinical investigation. Administered via subcutaneous injection in trials. Dosing protocols being established in phase 3 trials.
About Relamorelin
Relamorelin is a synthetic pentapeptide ghrelin receptor agonist developed for diabetic gastroparesis and chronic nausea/vomiting. It accelerates gastric emptying. Currently in clinical development.
Research Notes
Phase 3 trials ongoing for diabetic gastroparesis. Shows promise for accelerating gastric emptying in delayed emptying conditions. Development active.
Potential Side Effects
- •Generally well tolerated in trials
- •Possible injection site reactions
- •Investigational
Always consult with a healthcare professional before starting any peptide therapy.